^
Association details:
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review

Published date:
05/18/2022
Excerpt:
...we present an advanced ICC patient…As the next-generation sequencing (NGS) revealed BRAF V600E mutation in the tumor tissue, this patient was started on vemurafenib with a dosage of 720–960 mg BID and achieved 7 months progression-free survival with significant remission of clinical symptoms.
DOI:
10.1055/a-1826-2814